CD274 and pneumonitis: A multi-institutional cohort study recently has found that the risk of pneumonitis associated with PD-1/PD-L1 inhibitors compared with non-immunotherapy was 2.49% (95% CI: 1.50%-3.47%), and the median time to the onset of CIP was 3.9 months (IQR: 2.1-7.3) (20).